Last reviewed · How we verify
Fimasartan/Amlodipine, Rosuvastatin
This combination drug lowers blood pressure through angiotensin II receptor blockade and calcium channel inhibition, while simultaneously reducing cholesterol via HMG-CoA reductase inhibition.
This combination drug lowers blood pressure through angiotensin II receptor blockade and calcium channel inhibition, while simultaneously reducing cholesterol via HMG-CoA reductase inhibition. Used for Hypertension and dyslipidemia in patients requiring combination therapy.
At a glance
| Generic name | Fimasartan/Amlodipine, Rosuvastatin |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | Angiotensin II receptor antagonist / Calcium channel blocker / HMG-CoA reductase inhibitor (statin) |
| Target | AT1 receptor / L-type calcium channel / HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Fimasartan blocks angiotensin II type 1 receptors to reduce vasoconstriction and aldosterone secretion, amlodipine inhibits L-type calcium channels in vascular smooth muscle to promote vasodilation, and rosuvastatin inhibits HMG-CoA reductase to decrease LDL cholesterol synthesis. Together, these three agents address multiple cardiovascular risk factors—hypertension and dyslipidemia—in a single formulation.
Approved indications
- Hypertension and dyslipidemia in patients requiring combination therapy
Common side effects
- Dizziness
- Headache
- Peripheral edema
- Muscle pain or myalgia
- Elevated liver enzymes
Key clinical trials
- Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia (PHASE3)
- Comparison of Fimasartan Versus Amlodipine Therapy on Carotid PlaquE Inflammation (PHASE4)
- A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin (PHASE1)
- A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin (PHASE1)
- Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: